Search Results - "Doubre, H."

PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung by Damotte, D., Charpentier, M.C., Bernardi, M., Watkin, E., Goubin Versini, I., Lamy, R., Piton, N., Geriniere, L., Forest, F., Gervais, R., Monnet, I., Madrosyk, A., Guisier, F., Serrand, C., Locher Genty, C., Decroisette, C., Auliac, J.B., Jeanfaivre, T., Doubre, H., Arpin, D.

Get full text

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14 by Auliac, J B, Bayle, S, Vergnenegre, A, Le Caer, H, Falchero, L, Gervais, R, Doubre, H, Vinas, F, Marin, B, Chouaid, C

“…Mutations in are rare oncogene mutations, found in 2% of non-small-cell lung cancers (nsclcs). Little information is available about the management of patients…”
Get full text

Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study by FIZAZI, K, DOUBRE, H, LE CHEVALIER, T, RIVIERE, A, VIALA, J, DANIEL, C, ROBERT, L, BARTHELEMY, P, FANDI, A, RUFFIE, P

“…The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy…”
Get full text

Precision mass measurements of very short-lived, neutron-rich Na isotopes using a radio-frequency spectrometer by Lunney, D., Audi, G., Doubre, H., Henry, S., Monsanglant, C., de Saint Simon, M., Thibault, C., Toader, C., Borcea, C., Bollen, G.

Get full text

Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma by Fizazi, K, Caliandro, R, Soulié, P, Fandi, A, Daniel, C, Bedin, A, Doubre, H, Viala, J, Rodier, J.-M, Trandafir, L, Le Chevalier, T, Cvitkovic, E, Armand, J.-P, Ruffié, P

“…The aim of this study was to review the experience of the Institut Gustave Roussy in 163 patients with malignant mesothelioma over a 9-year period. Data from…”
Get full text

1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019) by Descourt, R., Guisier, F., Pérol, M., Cadranel, J., Duruisseaux, M., Doubre, H., Culine, S., Lamour, C., Moro-Sibilot, D., Mennecier, B., Martin, N., Bylicki, O., Chouaid, C., Greillier, L.

Get full text

1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy by Bronstein, A., Gervais, R., Monnet, I., Ricordel, C., Bigay-Game, L., Geier, M., Decroisette, C., Daniel, C., Guisier, F., Swalduz, A., Toffart, A.C., Doubre, H., Peloni, J.M., Arpin, D., Morel, H., Veillon, R., Clarisse, B., Chouaid, C., Greillier, L., Bylicki, O.

Get full text

52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study by Bilger, G., Girard, N., Doubre, H., Levra, M. Giaj, Leprieur, E. Giroux, Giraud, F., Decroisette, C., Livartowski, A., Massiani, M-A.

Get full text

1718P A French experience on COVID-19 and cancer from an academic general hospital in Paris area by Laurain, P.A., Landrin, T., Benmaziane Teillet, A., Sekkate, S., Billard, D., Lesprit, P., Couderc, L-J., Friard, S., Doubre, H., Beuzeboc, P., Ratta, R.

Get full text

1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study by Babey, H., Jamme, P., Gervais, R., Assié, J-B., Veillon, R., Doubre, H., Pérol, M., Guisier, F., Huchot, E., Decroisette, C., Falchero, L., Chiappa, A-M., André, M., Cortot, A.B., Chouaid, C., Le Gac, G., Descourt, R.

Get full text

1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies by Bylicki, O., Gervais, R., Monnet, I., Ricordel, C., Bigay-Game, L., Geier, M., Decroisette, C., Daniel, C., Guisier, F., Swalduz, A., Toffart, A.C., Doubre, H., Peloni, J.M., Arpin, D., Morel, H., Veillon, R., Clarisse, B., Martins-Lavinas, P-H., Greillier, L., Chouaid, C.

Get full text

1326P Liver metastasis but not bone metastasis impact overall survival of advanced non-small cell lung cancer (NSCLC) treated by nivolumab (GFPC 04-2016) by Decroisette, C., Guisier, F., Bylicki, O., Lamy, R., Geier, M., Morel, H., Bizieux, A., Vieillot, S., Bernardi, M., Janicot, H., Boissiere, L., Justeau, G., Gervais, R., Doubre, H., Le Garff, G., Vergnenegre, A., Chouaid, C.

Get full text

Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15 by Corre, R., Gervais, R., Tassy, L., Guisier, F., Lamy, R., Fraboulet, G., Greillier, L., Doubre, H., chouaid, C., Auliac, J.B.

Get full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

First results of a high precision mass measurement program for very short-lived nuclides by Toader, C., Monsanglant, C., Audi, G., Conreur, G., Doubre, H., Henry, S., Jacotin, M., Kepinski, J.F., Le Scornet, G., Lunney, D., De Saint Simon, M., Thibault, C., Kluge, H.-J., Borcea, C., Duma, M., Bollen, G.

“…The recent commissioning of the experimental program MISTRAL (Mass Measurements at ISolde using a Transmission and Radiofrequency spectrometer on Line) brought…”
Get full text

1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort by Baldacci, S., Besse, B., Avrillon, V., Mennecier, B., Dubray-Longeras, P., Mazieres, J., Descourt, R., Duruisseaux, M., Quantin, X., Doubre, H., Monnet, I., Moro-Sibilot, D., Schneider, S., Cousin, S., Merle, P., Otto, J., Langlais, A., Morin, F., Westeel, V., Girard, N.

Get full text

154PPD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung by Damotte, D, Charpentier, M C, Bernardi, M, Watkin, E, Goubin Versini, I, Lamy, R, Piton, N, Geriniere, L, Forest, F, Gervais, R, Monnet, I, Madrosyk, A, Guisier, F, Serrand, C, Locher Genty, C, Decroisette, C, Auliac, J B, Jeanfaivre, T, Doubre, H, Arpin, D

Get full text

Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14 by Auliac, J.B., Bayle, S., Vergnenegre, A., Fraboulet, G., Lecaer, H., Falchero, L., Dô, P., Doubre, H., Hauss, P.A., Vinas, A., Larive, S., Chiappa, A.M., Marin, B., Chouaid, C.

Get full text

Antitumoral effect of low molecular weight heparin in localized lung cancer. A randomized phase III controlled trial by Besse, B., Girard, P., Doubre, H., Charles-Nelson, A., Aquilanti, S., Izadifar, A., Azarian, R., Monnet, I., Lamour, C., Descourt, R., Oliviero, G., Taillade, L., Chouaid, C., Giraud, F., Falcoz, P -E, Revel, M -P, Westeel, V., Alifano, M., Chatellier, G., Meyer, G.

Get full text

Radiofrequency treatment of lung tumours by Mellot, F, Friard, S, Doubre, H, Guth, A, Chapelier, A, Scherrer, A, Couderc, L-J

“…Formal surgical resection is the standard treatment for patients with an operable non-small cell lung tumour and for selected patients with limited lung…”
Get full text